According to a report by Yole Développement, the CRISPR technology market is projected to reach $5 billion by 2023.

Replimune has been granted Breakthrough Therapy status for RP1 and has filed a Biologics License Application for RP1 with the FDA via the Accelerated Approval Pathway.

OncoVerity Raises Additional Series A Funds to Progress Cusatuzumab for Newly Diagnosed AML.

Vicebio Moves Forward with Clinical Trials for RSV/hMPV Bivalent Vaccine and Enhances Board by Appointing Industry Experts.

Jazz Pharmaceuticals has received U.S. FDA approval for Ziihera® (zanidatamab-hrii) to treat adults with HER2-positive (IHC 3+) biliary tract cancer (BTC).

Avirmax Biopharma Reports Dosing of First Patient in ABI-110 Clinical Study, a Novel Gene Therapy for Wet AMD with PCV.

Celldex reports that the first participant has received a dose in a Phase 1 study involving healthy volunteers for CDX-622.

LAPIX Therapeutics Reveals Favorable Phase 1 Clinical Trial Results for LPX-TI641 in Treating Autoimmune Disorders.

uniQure N.V. has announced that the initial patient has received the dose in the GenTLE Phase I/IIa clinical study of AMT-260.

Laekna has partnered with Lilly to advance LAE102, a new monoclonal antibody aimed at Activin Receptor Type 2A for obesity treatment.

The EC has given the green light to Pfizer’s HYMPAVZI™ (marstacimab) for treating severe Hemophilia A or B in adults and teens without inhibitors.

Eli Lilly and Company has announced encouraging Phase 2 findings for muvalaplin, which is a genetically linked risk factor for heart disease.